[Comparisons of efficacy and safety of CBV, BEAM and BEAC high-dose therapy followed by autologous hematopoietic stem cell transplantation in Hodgkin's lymphoma]

Y W Shi; P Liu; S Y Zhou; J L Yang; X H Han; X H He; C G Zhang; L Gui; Y Qin; S Yang; L Y Zhao; J R Yao; S X Zhang; S K Wu; F Pan; Y Sun; Y K Shi

doi:10.3760/cma.j.issn.0253-2727.2017.08.013

[Comparisons of efficacy and safety of CBV, BEAM and BEAC high-dose therapy followed by autologous hematopoietic stem cell transplantation in Hodgkin's lymphoma]

Zhonghua Xue Ye Xue Za Zhi. 2017 Aug 14;38(8):716-719. doi: 10.3760/cma.j.issn.0253-2727.2017.08.013.

[Article in Chinese]

Authors

Y W Shi, P Liu, S Y Zhou, J L Yang, X H Han, X H He, C G Zhang, L Gui, Y Qin, S Yang, L Y Zhao, J R Yao, S X Zhang, S K Wu, F Pan, Y Sun, Y K Shi¹

Affiliation

¹ Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National New Drug (Tumor Drug) Clinical Research Center, National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.

PMID: 28954353
PMCID: PMC7348237
DOI: 10.3760/cma.j.issn.0253-2727.2017.08.013

No abstract available

Grants and funding

基金项目：霍英东高等院校青年教师基金（B231996001）；人事部归国留学人员启动基金（B311994001）；卫生部优秀青年科技人才专项（B121994002）；国家“九·五”攻关课题（A20199610396-906-01-12）；高等学校博士学科点专项科研基金（20010023018、20050023045、B201995002）